JP Morgan Chase’s Apollo Endosurgery, Inc. APEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-1,338,150
Closed -$13.3M 7562
2023
Q1
$13.3M Buy
1,338,150
+263,800
+25% +$2.61M ﹤0.01% 2021
2022
Q4
$10.7M Buy
+1,074,350
New +$8.01M ﹤0.01% 2187
2022
Q2
Sell
-32,125
Closed -$194K 7097
2022
Q1
$194K Buy
32,125
+22,392
+230% +$136K ﹤0.01% 5209
2021
Q4
$82K Buy
+9,733
New +$85K ﹤0.01% 5767
2020
Q4
Sell
-7
Closed 6052
2020
Q3
$0 Hold
7
﹤0.01% 5894
2020
Q2
$0 Buy
+7
New +$14 ﹤0.01% 5811
2019
Q1
Sell
-600
Closed -$2K 6126
2018
Q4
$2K Sell
600
-57,827
-99% -$286K ﹤0.01% 5606
2018
Q3
$419K Buy
58,427
+46,995
+411% +$365K ﹤0.01% 4361
2018
Q2
$80K Buy
11,432
+8,157
+249% +$50.7K ﹤0.01% 4917
2018
Q1
$20K Buy
+3,275
New +$20.6K ﹤0.01% 5080
2017
Q4
Sell
-25,936
Closed -$119K 5630
2017
Q3
$119K Buy
+25,936
New +$137K ﹤0.01% 4257
2016
Q3
Sell
-127
Closed -$2K 4898
2016
Q2
$2K Buy
+127
New +$1.91K ﹤0.01% 4623

JP Morgan Chase's APEN Position: Q2 2023 in Review

JP Morgan Chase sold out of Apollo Endosurgery, Inc. (APEN) in Q2 2023, closing a stake of 1,338,150 shares — an estimated $13.3M sold.

JP Morgan Chase first reported a position in APEN in Q2 2016 and held it in 12 quarters. The position peaked at $13.3M in Q1 2023. 0 funds tracked by Wall St. Rank hold APEN as of Q2 2023.

  • JP Morgan Chase reported no remaining Apollo Endosurgery, Inc. position as of Q2 2023 after selling out during the quarter.
  • JP Morgan Chase sold 1,338,150 Apollo Endosurgery, Inc. shares in Q2 2023, an estimated $13.3M.
  • JP Morgan Chase first reported a position in Apollo Endosurgery, Inc. in Q2 2016 and held it in 12 quarters.
  • JP Morgan Chase's Apollo Endosurgery, Inc. position peaked at $13.3M in Q1 2023.
  • 0 funds tracked by Wall St. Rank held Apollo Endosurgery, Inc. as of Q2 2023.

Based on JP Morgan Chase's 13F filing for Q2 2023, filed 11 Aug 2023.